Companies in #Alzheimer's Disease Agitation
Found 2 companies operating in this sector.
Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.
Neumora Therapeutics is a clinical-stage neuroscience company in Watertown, Massachusetts, developing small-molecule medicines for brain diseases with high unmet need. Its lead programme navacaprant (NMRA-140), a kappa opioid receptor antagonist, was discontinued in June 2026 after the Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder failed to reach statistical significance on primary and key secondary endpoints, a decision accompanied by a workforce reduction of roughly 35%. The company has since re-based its pipeline on three earlier assets: NMRA-511, a vasopressin 1a receptor antagonist in Alzheimer's disease agitation that has reported a Phase 1b clinical signal and is moving into higher-dose and Phase 2 work; NMRA-898, an M4 positive allosteric modulator in schizophrenia; and NMRA-215, an NLRP3 inhibitor for obesity and cardiometabolic disease. Neumora held $116.8 million in cash and equivalents at June 30, 2026, guided to fund operations into the third quarter of 2027, and in October 2026 received a Nasdaq notice that its share price had traded below the $1.00 minimum bid for 30 consecutive business days, with until April 26, 2027 to regain compliance and a reverse stock split under consideration.